442 material Form 8-K filings that 386 companies we cover made with the SEC in March 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Concentrix reported first-quarter fiscal 2025 results for the period ended February 28, 2025. Revenue fell 1.3% from a year earlier to $2.37 billion, while GAAP diluted earnings per share rose 36.8% to $1.04 and non-GAAP diluted EPS rose 8.6% to $2.79. The company reiterated its full-year fiscal 2025 guidance and gave second-quarter outlook figures.
Q1 revenue of $2,372.2 million, down 1.3% year-on-year as reported and up 1.3% in constant currency
GAAP diluted EPS of $1.04 versus $0.76; non-GAAP diluted EPS of $2.79 versus $2.57
Adjusted free cash flow was a use of $39.8 million in the quarter; full-year adjusted free cash flow expected at $625 million to $650 million
Second-quarter non-GAAP EPS expected at $2.69 to $2.80; full-year fiscal 2025 reported revenue expected at $9.490 billion to $9.635 billion
REX American Resources reported lower fourth-quarter and full fiscal 2024 sales and profit than a year earlier, as lower ethanol and co-product prices reduced revenue. Diluted EPS was $0.63 in the quarter versus $1.16, and $3.30 for the full year versus $3.47. The company also said its One Earth ethanol expansion will finish later than the mid-2025 target and now has a budget of $220-$230 million.
Q4 net sales and revenue were $158.2 million versus $187.6 million; Q4 gross profit was $17.6 million versus $30.4 million.
Full fiscal 2024 net sales and revenue were $642.5 million versus $833.4 million; diluted EPS was $3.30 versus $3.47.
One Earth ethanol expansion is budgeted at $220-$230 million, with completion now expected after the middle of 2025.
On March 25, 2025, the board authorized up to 1.5 million additional shares for repurchase; the company reported $359.1 million in cash and short-term investments and no bank debt as of January 31, 2025.
Paychex reported third-quarter fiscal 2025 results for the period ended February 28, 2025, with total revenue up 5% to $1.5 billion and diluted earnings per share up 4% to $1.43. The company also updated its fiscal 2025 outlook, now expecting PEO and Insurance Solutions revenue growth of 6.0% to 6.5% and an adjusted operating margin of about 43%, while the pending Paycor acquisition, expected to close in April 2025, is excluded from that outlook.
Total revenue was $1,509.0 million for the quarter, up 5% from $1,439.3 million a year earlier.
Diluted EPS was $1.43, up 4%; adjusted diluted EPS was $1.49, up 8%.
Fiscal 2025 outlook: PEO and Insurance Solutions revenue growth of 6.0% to 6.5%; adjusted operating margin about 43%.
The Paycor acquisition, agreed January 7, 2025, is expected to close in April 2025; the Hart-Scott-Rodino waiting period expired February 27, 2025.
Cintas reported fiscal 2025 third-quarter revenue of $2.61 billion, up 8.4%, and diluted EPS of $1.13, up 17.7% from $0.96 a year earlier. The company raised its fiscal 2025 diluted EPS guidance to $4.36 to $4.40 from $4.28 to $4.34, while narrowing its revenue guidance to $10.280 billion to $10.305 billion.
Q3 net income was $463.5 million, up 16.6%, and gross margin was 50.6% of revenue versus 49.4% a year earlier.
Q3 operating income included a $15.0 million gain on the sale of property and equipment; the prior-year quarter included a $15.0 million class action settlement charge.
Fiscal 2025 diluted EPS guidance rose to $4.36 to $4.40 from $4.28 to $4.34.
Fiscal 2025 revenue guidance is $10.280 billion to $10.305 billion, versus the prior $10.255 billion to $10.320 billion; the top end was lowered by $15.0 million due to currency effects.
Chewy reported fiscal fourth-quarter and full-year 2024 results, with net sales up 14.9% in Q4 and 6.4% for the year. Q4 GAAP net income and diluted EPS declined year over year, while adjusted EBITDA rose 44% and full-year net income increased, helped by a $241.0 million income tax benefit. Both quarter and year include an extra week, which the company notes affects the comparisons.
Q4 net sales of $3.25 billion, up 14.9% year over year (14-week quarter)
Q4 net income of $22.8 million and diluted EPS of $0.05, versus $31.9 million and $0.07 a year earlier
Q4 adjusted EBITDA of $124.5 million, up $38.1 million; full-year net income of $392.7 million
Fiscal 2024 repurchases of common stock totaled $942.8 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.